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Abstract
Background: A promising new approach in cancer therapy is the use of tumor specific antibodies coupled to
cytotoxic agents. Currently these immunoconjugates are prepared by rather unspecific coupling chemistries,
resulting in heterogeneous products. As the drug load is a key parameter for the antitumor activity, site-specific
strategies are desired. Expressed protein ligation (EPL) and protein trans-splicing (PTS) are methods for the specific
C-terminal modification of a target protein. Both include the expression as an intein fusion protein, followed by the
exchange of the intein for a functionalized moiety.
Results: A full-length IgG specific for fibronectin ED-B was expressed as fusion protein with an intein (Mxe GyrA or
Npu DnaE) attached to each heavy chain. In vitro protocols were established to site-specifically modify the
antibodies in high yields by EPL or PTS, respectively. Although reducing conditions had to be employed during the
process, the integrity or affinity of the antibody was not affected. The protocols were used to prepare
immunoconjugates containing two biotin molecules per antibody, attached to the C-termini of the heavy chains.
Conclusion: Full-length antibodies can be efficiently and site-specifically modified at the C-termini of their heavy
chains by intein-fusion technologies. The described protocols can be used to prepare immunoconjugates of high
homogeneity and with a defined drug load of two. The attachment to the C-termini is expected to retain the
affinity and effector functions of the antibodies.
Background
Monoclonal antibodies have been approved as therapeutic
agents for indications including viral infections, immuno-
logical disorders, transplant rejection and cancer [1]. They
often act by blocking the function of their target molecule.
More demanding is the therapy of cancer by antibodies
requiring the specific recognition and subsequent elimina-
tion of tumor cells.
Several mechanisms have been described how thera-
peutic antibodies elicit cell death, including the triggering
of apoptosis and the recruitment of the immune system.
While therapeutic antibodies have been approved work-
ing by these mechanisms (e.g. Rituximab [2], Trastuzu-
mab [3], Alemtuzumab [4]) their cytotoxic potential is
generally not sufficient to completely eliminate the
malignant cells. Higher efficacies have been observed if
the antibody is coupled to toxic agents like radioisotopes
(radioimmunoconjugates) or chemical drugs (antibody-
drug-conjugates, ADC) [5]. Several of these conjugates
have been approved for cancer (Ibritomomab, Tositumo-
mab) or are in clinical development (e.g. Trastuzumab-
DM1).
Coupling of toxic agents to therapeutic antibodies also
paves the way for new tumor associated antigens as these
are not required to be present on the surface of the malig-
nant cells. An example is the extra domain B (ED-B) of
fibronectin, a protein of the extracellular matrix. ED-B-
containing fibronectin is a splice variant associated with
angiogenesis and tissue remodeling [6]. High levels of ED-
B expression have been detected in most solid tumors and
in vivo studies with ED-B specific monoclonal antibody
formats show the selective accumulation in tumors and
metastases. Accordingly, ED-B is a promising target for
antibody-based cancer treatment [7,8] and the results of
first clinical trials with ED-B specific antibody fragment
conjugates are encouraging [9,10].
Current methods for the preparation of immunoconju-
gates rely on the chemical coupling to lysine, cysteine or
tyrosine side chains [11]. These methods are rather
* Correspondence: axel.harrenga@bayer.com
3Bayer Healthcare, Nattermannallee 1, 50829 Cologne, Germany
Full list of author information is available at the end of the article
Möhlmann et al. BMC Biotechnology 2011, 11:76
http://www.biomedcentral.com/1472-6750/11/76
© 2011 Möhlmann et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
unspecific and result in heterogeneous products. As the
drug load - number of toxophore per antibody - is a key
parameter for the antitumor activity of immunoconju-
gates [12-14] more site-specific coupling reactions are
desired. Approaches employing the carbohydrate moi-
eties [15,16], the N- and the C-terminus [17,18] of full-
length IgG antibodies have been described. However, the
carbohydrates are important for the effector functions of
the Fc domain [19] and the N-terminus of antibodies is
close to their antigen binding site which may result in
decreased affinity after modification. This leads to the C-
terminus as a preferred site for specific drug attachment.
Several enzymatic approaches have been described for
the modification of protein C termini [20]. They have in
common that the target protein is expressed in fusion
with a C-terminal tag containing the modification site. A
common drawback of these methods is an incomplete
conversion. Without the possibility for separation, this
would result in heterogeneous preparations of low aver-
aged drug loads. Interestingly, the intein tag is cleaved off
from the target protein during modification, facilitating
preparative separation of modified from non-modified
protein. Inteins encompass catalytic domains which lead
to the formation of a thioester bond at their junction to
the target protein. This thioester bond can be employed to
exchange the intein for a C-terminal probe. The probe is
eventually connected via a native peptide bond [21].
Methods for intein-mediated C-terminal protein modifi-
cation encompass expressed protein ligation (EPL) and
protein trans-splicing (PTS). In EPL, the target protein is
fused to a modified full-length intein. The intein is cleaved
off by the addition of a thiol reagent, leaving a thioester
bond (first step), and the target protein is ligated to a
probe functionalized with an N-terminal cysteine residue
(second step) [22,23]. In PTS, inteins are used which are
split into two parts with high affinity to each other. The
large N-terminal part is fused to the target protein. The
probe is functionalized with the small C-terminal part of
the intein. Their combination results in a functional intein,
which splices itself out and concomitantly fuses the target
protein to the probe [24-26].
Intein-fusion technologies have already been used for
several applications, including the derivatization of small
single-chain and single-domain antibody formats with
fluorophores and micelles, respectively [27-29]. Here we
explored the use of two distinct inteins for C-terminal
modification of a full-length antibody. The first is the
GyrA intein from Mycobacterium xenopi (Mxe) which is a
‘minimal’ intein of 198 residues [30]. It can be used for
protein modification by EPL [31]. The second is the split
DnaE intein from Nostoc punctiforme (Npu) [32,33]. It
consists of an N-terminal part of 102 residues and a
C-terminal of 36 residues. Npu DnaE was employed for
protein modification by PTS. Each intein was fused to the
heavy chain of anti ED-B IgG1, resulting in two inteins per
antibody (Figure 1). The fusion proteins were expressed by
secretion from transfected human embryonic kidney
(HEK) cells. After purification, in vitro cleavage by Mxe
GyrA or trans-splicing by Npu DnaE yielded 60% or 80%,
respectively, of completely processed antibody. The proto-
cols described resulted in functional antibodies and were
used to generate immunoconjugates containing two biotin
moieties per protein molecule, attached site-specifically to
the C-termini of the heavy chains.
Results and Discussion
Production of L19 IgG antibodies with C-terminal intein
domains
Antibodies require an oxidizing environment for their
expression as they contain several disulfide bonds impor-
tant for proper folding. In addition, glycosylation has been
shown to be important for the effector functions of antibo-
dies [19]. They are therefore usually produced by mamma-
lian expression systems. We chose transiently transfected
HEK293-6E cells for the expression of L19 IgG antibody
which is specific for the ED-B domain of fibronectin.
Endogenous signal sequences ensure the secretion into the
extracellular medium and therefore the proper folding of
the immunoglobulin domains. Connected via an 11 resi-
due linker, the heavy chain was fused to an intein domain.
We tested two distinct inteins, GyrA from Mycobacterium
xenopi [31] and the split intein DnaE from Nostoc puncti-
forme [32]. In case of DnaE, L19 IgG was fused to the
N-terminal domain DnaEN (residues 1-102). Both inteins
were extended C-terminally by a decahistidine tag for pur-
ification purposes.
Antibody-intein fusion proteins were obtained in good
yields (90-110 mg/L). They were purified by His tag affi-
nity chromatography and subsequent gel filtration. A com-
mon problem with GyrA fusion proteins is the occurence
of intein cleavage during expression. This in vivo cleavage
decreases the product yield and is detectable by the co-
purification of the separated intein domain after His Tag
affinity chromatography (Figure 2). However, judged by
the subsequent gel filtration elution profile (not shown),
only 10-15% in vivo cleavage was observed for GyrA.
DnaEN showed no in vivo cleavage as expected for a split
intein.
Preparation of immunoconjugates by Mxe GyrA intein
mediated EPL
In vitro cleavage of L19 IgG-GyrA fusion protein was
induced by the addition of 50 mM Mesna which has
been reported to form a long-living thioester at the C-
terminus. This thioester can be employed to link to the
IgG a probe that is functionalized with an N-terminal
cysteine residue. It is added concomitantly with Mesna
but in lower concentration (5 mM). The cysteine replaces
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the Mesna-thioester, resulting in a stable peptide bond
between the IgG and the probe (Figure 1).
To study the cleavage efficiency of the L19 IgG-GyrA
fusion protein and to test the antibody integrity after
EPL, cysteine was used as ‘probe’. After 22h, Mesna and
cysteine were removed by intensive dialysis to regener-
ate and stabilize the disulfide bonds of the antibody. L19
IgG cleaved on both heavy chains could be separated
from non- or partly-cleaved antibody by His Tag affinity
chromatography (Figure 3). The yield of completely
cleaved antibody was about 60%. To test if its function-
ality had been damaged by the reducing conditions used
during EPL it was intensively analyzed. SDS-PAGE
under non-reducing conditions resulted in a single band
at 150 kDa (calculated: 146.3 kDa), showing that inter-
chain disulfide bonds were intact (Figure 4A). Analytical
gel filtration confirmed the integrity of the antibody,
eluting in a single peak very similar to unmodified L19
IgG (control antibody) (Figure 4B). Finally, interaction
studies by Surface Plasmon Resonance (SPR) were
employed to evaluate antibody functionality after EPL.
The antigen binding part was analyzed by investigation
of the interaction with the ED-B domain. Binding
kinetics and the dissociation constant (~90 nM) were
the same as for the L19 IgG control antibody (Figure
4C). To test the functionality of the Fc part, the interac-
tion with the high affinity Fcg RI/CD64 and with the
low affinity Fcg RIIIA/CD16a was analyzed by SPR.
Binding kinetics and the dissociation constants for both
Fcg receptors (Fcg RI/CD64: ~0.2 nM; Fcg RIIIA/CD16a:
~60nM) did not change significantly demonstrating pre-
servation of full functionality (see Additional file 1). In
summary, these results show that antigen binding as
well as effector functions of L19 IgG have not been
affected by the EPL process.
A side reaction of EPL is the hydrolysis of the thioester
instead of its derivatization with cysteine. To estimate the
yield of L19 IgG-Cys, a pepsin digest assay was employed.
Pepsin can be used to prepare Fab dimers from an IgG1
as it cleaves C-terminal to the interchain disulfide bonds
connecting the heavy chains [34]. The Fc part of the anti-
body is cleaved into several fragments. Mass spectrome-
try analysis of L19 IgG control antibody after pepsin
digest (pH 4.5) revealed that the most C-terminal clea-
vage site is the linker between CH2 and CH3 domain,
leaving the CH3 domain intact (Figure 5A). This could
Figure 1 Illustration of chemical steps during in vitro processing of IgG-intein fusion protein. Above the arrow, the chemistry of GyrA
intein is shown. After intein-catalyzed N-S acyl shift, GyrA is substituted by Mesna. Mesna-thioester is cleaved by the probe functionalized with
an N-terminal cysteine residue, and finally rearranges to a stable peptide bond. Below the arrow, the chemistry of DnaE intein is shown. The
intein has to be activated by association of its N- and C-terminal part. The probe is attached to the C-terminal part and transferred after the
intein-catalyzed N-S acyl shift.
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be used for the observation of cysteine derivatization: If
cysteines are attached C-terminal to the heavy chains
they are expected to form an interchain disulfide bond,
resulting in a 28 kDa fragment under non-reducing con-
ditions. However, if one or both cysteines are missing, 14
kDa fragments are observed. Non-reducing SDS-PAGE
after pepsin digest of L19 IgG-Cys revealed the occur-
rence of a 28 kDa band which was replaced by a 14 kDa
band after reduction (Figure 5B). Both bands were
excised from the gel and analyzed after tryptic digest
with HPLC ESI-Q-TOF. Clearly, only peptides from the
CH3 domain were found (Figure 5C). Also the C-term-
inal peptide was observed, carrying the cysteine. Interest-
ingly, the 14 kDa band is hardly detectable on the non-
reducing SDS-PAGE gel. Mass spectrometry analysis of a
non-reduced sample after pepsin digest confirmed this
observation: We detected a 28 kDa fragment but no 14
kDa fragment (Figure 5C). We conclude that the fraction
of hydrolyzed protein is minor and that cysteine deriva-
tized L19 IgG was obtained in high yield. This would
result in a homogeneous drug load of two. In addition, a
C-terminal disulfide bond is readily formed. This may
stabilize the immunoconjugate and hinders undesired
side reactions of thiol groups in the oxidizing environ-
ment antibodies are held.
The aim of our work was to use GyrA intein for the
attachment of probes functionalized with an N-terminal
cysteine residue. To show the usability of the protocol
for this purpose, a CysLys-Biotin peptide was added
instead of cysteine. After SDS-PAGE and Western blot-
ting, the specific attachment of biotin to the heavy chain
was verified by Streptavidin-based staining (Figure 6). In
summary, the described EPL protocol is applicable for
the site specific modification of full-length IgG by
probes attached to an N-terminal cysteine residue.
Preparation of immunoconjugates by Npu DnaE intein
catalyzed PTS
L19 IgG-DnaEN contains an incomplete intein which
was activated in vitro by the addition of a peptide com-
prising the missing C-terminal 36 residues, followed by
the naturally occurring post-intein sequence CFN. This
DnaEC peptide can be employed to transfer a C-termin-
ally attached probe to L19 IgG by PTS (Figure 1).
Importantly, trans-splicing was only observed under
reducing conditions i.e. after the addition of 5 mM
DTT. We propose that this is due to the requirement of
a free cysteine in the reactive center of DnaE intein.
To establish the PTS protocol, DnaEC peptide without
a probe was used. After 24h trans-splicing reaction,
DTT was removed by dialysis and completely spliced
Figure 2 In vivo cleavage. Mammalian expression medium was
conducted to His tag affinity chromatography and the eluate was
analyzed by reducing SDS-PAGE (Coomassie stained). 10-15% of L19
IgG-GyrA is cleaved during expression. L19 IgG-DnaEN shows no in
vivo cleavage (HC: heavy chain, LC: light chain).
Figure 3 L19 IgG-GyrA after EPL. Analysis by reducing SDS-PAGE
(Coomassie stained). Purified fusion protein was treated with 50
mM Mesna and 5 mM cysteine for 22h at RT. After dialysis, cleaved
L19 IgG was purified by His tag affinity chromatography (1: L19 IgG-
GyrA before cleavage, 2: after cleavage, before purification, 3: after
purification, HC: heavy chain, LC: light chain).
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L19 IgG was purified by His tag affinity chromatography
(Figure 7). The yield of L19 IgG processed on both
heavy chains was about 80%. Analysis were undertaken
to test if the antibody had been damaged by the redu-
cing conditions used during PTS. SDS-PAGE under
non-reducing conditions showed that interchain disul-
fide bonds were intact as a main band at 150 kDa (cal-
culated: 146.9 kDa) was observed (Figure 8A). However,
a weak band corresponding to a protein species with an
apparent molecular mass of 300 kDa indicated the pre-
sence of a small amount of antibody dimers. These
results were confirmed by analytical gel filtration (Figure
8B). L19 IgG-DnaEN trans-splicing product eluted in a
main peak very similar to unmodified L19 IgG (control
antibody) but is accompanied by a small preceding peak
typical for dimerization. We conclude that the integrity
of L19 IgG is retained after PTS. The small percentage
of dimerization could be due to some degree of
Figure 4 Analysis of L19 IgG-GyrA integrity after EPL. (A) Non-reducing (ox) and reducing (red) SDS-PAGE (Coomassie stained). (B) Analytical
Gel Filtration. Black: L19 IgG-GyrA before cleavage. Dotted: Purified EPL product. Grey: L19 IgG control antibody. (C) SPR analysis. Results were
fitted to a one-site-binding model with a KD of 91.4 nM.
Figure 5 High yield of cysteine derivatization after L19 IgG-GyrA in vitro cleavage. Purified EPL product was pepsin digested. (A) Scheme
indicating observed pepsin cleavage sites. (B) SDS-PAGE analysis (Coomassie stained). Non-reducing (ox) conditions show the Fab dimer and a
prominent 28 kDa band. After reduction (red), a 14 kDa band is observed. (C) Mass spectrometry analysis results, illustrated by the amino acid
sequence of L19 IgG Fc domain. A sample after pepsin digest was analyzed by ESI-TOF. Two prominent masses were found: The Fab dimer
(calculated: 96061.5, observed: 96061.2 Da) and a fragment (calculated: 27857.1 Da, observed: 27856.3 Da) corresponding to a disulfide
connected CH3 domain cleaved at the indicated site (asterisk). Sequence analysis was performed by tryptic in-gel digest of the 28 kDa and 14
kDa band in (B) followed by ESI-Q-TOF. Only sequences of the CH3 domain were observed. Bold: Immunoglobuline domains (CH2 and CH3).
Underlined: Sequences found in the 28 kDa and 14 kDa band. Dashed underlined: Sequences only found in the 14 kDa band.
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hydrolysis during intein catalyzed trans-splicing (see
below). This would result in antibodies with single
cysteine residues at the C-terminus which are prone to
pairing by disulfide bond formation. To test the func-
tionality of L19 IgG after PTS, its interaction with the
ED-B domain was analyzed by SPR. Binding kinetics
and the dissociation constant (~90 nM) were the same
as for the L19 IgG control antibody (Figure 8C). In
addition, the interaction with the high affinity Fcg RI/
CD64 and with the low affinity Fcg RIIIA/CD16a was
investigated by SPR. Binding kinetics and the dissocia-
tion constants for both Fcg receptors (Fcg RI/CD64:
~0.2 nM; Fcg RIIIA/CD16a: ~60nM) were not compro-
mised by PTS, demonstrating the full functionality of
the Fc domain (see Additional file 1). In summary, our
DnaE PTS protocol does neither affect the integrity nor
the functionality of L19 IgG.
In the next step we used the DnaE intein to attach
biotin probes to the antibody. A functionalized DnaEC
peptide (DnaEC-CFNK-Biotin) was applied according to
our protocol and the L19 IgG product was analyzed by
SDS-PAGE and Western blotting (Figure 9). Biotin was
specifically attached to the heavy chain.
The requirement to synthesize a 39 residue peptide
(DnaEC-CFN) makes the described protocols for attach-
ment of small probes more complicated with DnaE than
with GyrA. However, as DnaEC begins on a methionine
residue, it can easily be expressed in vivo at the N-termi-
nus of a fusion protein. Proteins like exotoxins, RNases
or cytokines have been described to be effective against
tumor cells if fused to a targeting antibody [35]. In con-
trast to IgGs, these effector proteins can usually be pro-
duced by bacterial expression systems. We suggest that
DnaE catalyzed PTS could be used to combine a given
antibody with a diversity of effector proteins. To test our
protocol for this purpose, DnaEC fused to glutathione-S-
transferase (GST) was purified from recombinant E. coli
and incubated with L19 IgG-DnaEN. Analysis by reducing
SDS-PAGE showed that a main product of 80 kDa had
been formed (Figure 10A). This corresponds to the heavy
chain fused to GST (calculated: 76.8 kDa). Western blot-
ting confirmed the presence of GST in the band (Figure
10B). In summary, our DnaE PTS protocol is suitable to
obtain L19 IgG antibody functionalized with probes or
effector proteins in good yield.
L19 IgG heavy chain conjugated to GST (80 kDa) was
the main product after PTS with DnaEC-GST as probe.
Figure 6 Biotinylation of L19 IgG-GyrA after in vitro cleavage.
EPL was performed with 50 mM Mesna and 5 mM CysLys-Biotin,
the product was purified by His tag affinity chromatography and
analyzed by reducing SDS-PAGE. Western blotting with Streptavidin-
Alkaline-Phosphatase revealed specific biotin derivatization of the
heavy chain.
Figure 7 L19 IgG-DnaEN after PTS. Analysis by reducing SDS-
PAGE (Coomassie stained). Purified fusion protein was treated with
5 mM DTT and 50 μM DnaEC peptide for 22h at RT. After dialysis,
trans-spliced L19 IgG was purified by His tag affinity
chromatography (1: L19 IgG-DnaEN before PTS, 2: after PTS, before
purification, 3: after purification, HC: heavy chain, LC: light chain, *
product not further investigated).
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Figure 8 Analysis of L19 IgG-DnaEN integrity after PTS. (A) Non-reducing (ox) and reducing (red) SDS-PAGE (Coomassie stained). (B)
Analytical Gel Filtration. Black: L19 IgG-DnaEN before PTS. Dotted: Purified PTS product. Grey: L19 IgG control antibody. (C) SPR analysis. Results
were fitted to a one-site-binding model with a KD of 83.4 nM.
Figure 9 Biotinylation of L19 IgG-DnaEN by PTS. Trans-splicing
was initiated with 50 μM DnaEC-CFNK-Biotin in the presence of 5
mM DTT. After purification by His tag affinity chromatography, the
product was analyzed by reducing SDS-PAGE and Western blotting.
Staining with Streptavidin-Alkaline-Phosphatase revealed specific
biotin derivatization of the heavy chain.
Figure 10 GST transfer to L19 IgG-DnaEN by PTS . Intein
activation was performed with 5 mM DTT and 50 μM DnaEC-GST
and analyzed by reducing SDS-PAGE. (A) Coomassie staining
revealed HC-GST (~80 kDa) as main product and HC as side
product. 1: DnaEC-GST. 2: L19 IgG-DnaEN. 3: L19 IgG-DnaEN + DnaEC-
GST. (B) Western blotting with anti-GST antibody confirmed the
transfer of GST onto the heavy chain of L19 IgG (HC: heavy chain,
LC: light chain).
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However, also a side product of 50 kDa was observed. It
corresponded to the heavy chain of L19 IgG produced
by hydrolysis of the thioester intermediate formed dur-
ing intein catalysis and allowed evaluation of its magni-
tude compared to probe conjugation. We estimate from
the gel that about 25% of processed heavy chain was
hydrolyzed while about 75% encompassed the desired
conjugation product. Due to this hydrolysis, the drug
load of immunoconjugates prepared by our DnaE PTS
protocol reached only about 1.5. It is likely that hydroly-
sis was promoted by attack of the thiol reagent DTT on
the intein-derived thioester [33]. DTT had to be added
to ensure reducing conditions for optimal intein activity.
Alternative reducing agents like tris(2-carboxyethyl)
phosphine (TCEP) could decrease hydrolysis and further
optimize the PTS protocol.
Conclusions
We have shown here for the first time that full-length
IgGs can be specifically functionalized at the C-terminus
of their heavy chains by EPL and PTS. Antibodies pro-
cessed on both chains were obtained in good yields and
purified from incompletely processed proteins. The attach-
ment of two probes per antibody and in vicinity to each
other yielded an additional disulfide bond, circumventing
problems with free thiol groups introduced by intein-
fusion technologies. These methods could be employed to
generate immunoconjugates of high homogeneity and
with a drug load of two. The modification at the C-termini
of the heavy chains does not interfere with antigen binding
and, judged by binding to Fcg RI and Fcg RIIIA, it does not
compromise the effector functions of the Fc domain. Pro-
vided with an effective toxophore, this would result in




Chemicals were purchased from Sigma Aldrich if not
stated otherwise. Chromatography material (Glutathione
Sepharose 4 Fast Flow, HiTrap Chelating HP, Superdex
200) was obtained from GE Healthcare (Munich).
Vectors
L19 IgG was derived by transferring the variable
domains of L19 scFv [36] into a human IgG1/к format.
Mxe GyrA (from vector pTXB1, New England Biolabs)
or Npu DnaEN (from vector pSKDuet, provided by
Hideo Iwai, University of Helsinki) were cloned behind
the heavy chain of L19 IgG, separated by a linker coding
for GLEGGSGGSEY. GyrA and DnaEN were extended
C-terminally to include a His tag (GSA-H10 and AS-H10,
respectively). Constructs encoding L19 IgG (control,
without linker) and L19 IgG fused to GyrA or DnaEN
were transferred into pTT5 vector (National Research
Council Canada). In the resulting expression vectors,
both, heavy and light chain, were under the control of
an hCMV promoter.
DNA encoding DnaEC from Nostoc punctiforme
(MIKIATRKYLGKQNVYDIGVERDHNFALKNGFIASN
[32]), followed by a linker (CFNPAGSSGVIM) and Glu-
tathione-S-Transferase (GST, Schistosoma japonicum)
was purchased from Geneart (Regensburg, Germany),
amplified by PCR and ligated into vector pET29a (Nova-
gen) by NdeI/NotI.
Expression and Purification of L19 IgG constructs
0.5 L of HEK293-6E cells were grown in F17 medium with
4 mM GlutaMAX-I and 0.1% Pluronic F-68 (Invitrogen)
to a density of 1.5 - 2.0 × 106 cells/mL and transfected
with 500 μg plasmid DNA (L19 IgG constructs) as
described [37], with minor modifications. After five days
cells were harvested by centrifugation (8000 × g, 5’).
The supernatant was concentrated to 50 mL by crossflow
filtration (Sartorius) and dialyzed against column buffer
(500 mM NaCl, 50 mM Hepes-NaOH, pH 7.5). For purifi-
cation, Ni-loaded IMAC (elution with imidazole gradient)
and subsequent gel filtration was applied.
Expression and Purification of DnaEC-GST
E. coli BL21-Star (DE3) (Invitrogen) was transformed
with vector DnaEC-GST-pET29a. Medium 2xYT (Difco)
containing 50 μg/mL kanamycin was inoculated with an
overnight culture and grown at 37°C, 220 rpm. At an
OD600 of 0.4 temperature was decreased to 16°C. Protein
expression was induced with 0.3 mM IPTG at an OD600
of 0.8. After 48 h cells were harvested (3,000 × g, 20’) and
suspended in buffer (500 mM NaCl, 50 mM Tris-HCl pH
7.5, 2 mM b-mercaptoethanol). Cell lysate was obtained
by high pressure homogenization (Constant cell disrup-
tion systems, Constant Systems Ltd, UK) and subsequent
centrifugation (20,000 × g, 30’). Purification of DnaEC-
GST protein was achieved by applying Glutathione
Sepharose (500 mM NaCl, 50 mM Tris-HCl pH 7.5,
2 mM b-mercaptoethanol, elution with 10 mM reduced
glutathione), followed by gel filtration (500 mM NaCl,
50 mM Hepes-NaOH, pH 7.5).
Intein catalyzed protein modification
For GyrA mediated EPL, 5 μM L19 IgG-GyrA was incu-
bated in 500 mM NaCl, 50 mM Hepes-NaOH, pH 8.0, 50
mM Mesna (2-mercaptoethane sulfonate-sodium), 5 mM
cysteine or Bio-P1 Peptide (NEB). For DnaE mediated
protein trans-splicing, 5 μM L19 IgG-DnaEN was mixed
with 50 μM DnaEC Peptide (MVKVIGRRSLGVQRIF-
DIGLPQDHNFLLANGAIAANCFN, kind gift from Prof.
Christian Becker, TU Munich, Germany. The sequence
corresponds to DnaEC from Synechocystis sp. strain
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PCC6803 (Ssp) which is interchangeable with Npu DnaEC
[32]), DnaEC-Biotin (MVKVIGRRSLGVQRIFDIGLPQDH
NFLLANGAIAANCFNK-Biotin, synthesis by JPT Peptide
Technologies GmbH, Berlin, Germany) or DnaEC-GST in
500 mM NaCl, 50 mM Hepes-NaOH, pH 7.5, 5 mM
DTT. After incubation for 22-24h at room temperature
(RT), intein activity was stopped by removing reducing
agents (Mesna, DTT, cysteine) by dialysis over night at
RT. For purification, the sample was loaded onto a Ni-I-
MAC column (500 mM NaCl, 50 mM Hepes-NaOH, pH
7.5). Completely processed L19 IgG was not in the flow
through but was eluted at 30 mM imidazole. Partly- or
non-processed L19 IgG-GyrA or -DnaEN was eluted with
300 mM imidazole. For subsequent analysis, protein was
dialyzed against 500 mM NaCl, 50 mM Tris-HCl, pH 7.5
and concentrated to 1-2 mg/mL.
SEC
A sample (~50 μg) was loaded onto a gel filtration column
connected to an HPLC instrument (Agilent Technologies
1200 Series) equipped with detectors for refractive indices
(RI) and multi angle light scattering (MALS) (Optilab rEX
and miniDAWN TREOS, Wyatt Technology Corp., Santa
Barbara, CA). To calculate the yield of intein processing, a
sample after EPL/PTS but before purification was ana-
lyzed. The mass of the excised intein was determined by
its RI signal and set into relation to the total loaded mass.
Pepsin digestion and mass spectrometry
L19 IgG was dialyzed against 20 mM NaAcetat pH 4.5.
Pepsin (Protea Biosciences) was added to give an
enzyme-to-antibody ratio of 1:25 (w:w) and incubated
for 24h at 37°C. A sample was directly analyzed by ESI-
TOF to assess masses of peptides derived by the Pepsin
digest. Further samples were separated by reducing and
non-reducing SDS-PAGE and gels were Coomassie
stained. Protein bands were excised, de-stained, reduced
with DTT, alkylated with iodacetamide and digested
with trypsine. Protein sequences were determined by
ESI-Q-TOF (MS and MS/MS) and search in Sequest
(Finnigan) and Mascot Databases.
Western blot
After SDS-PAGE, gels were blotted onto a nitrocellulose
membrane (iBlot, Invitrogen) and incubated for 1h in
blocking buffer (TBS with 0.05% (v/v) Tween-20 and 5%
(w/v) milk powder). Biotin was detected by incubating
with 1 μg/ml Streptavidin-Alkaline Phosphatase (Sigma) in
blocking buffer over night. GST was detected by over
night incubation with anti-GST antibody (GE Healthcare,
1:5000 in blocking buffer) followed by 1h incubation with
anti-Goat IgG-Alkaline Phosphatase (Sigma, 1:1000 in
blocking buffer) as secondary antibody. BCIP/NBT (Sig-
maFAST tablet) was used for membrane staining.
Surface Plasmon resonance (SPR)
A Biacore T100 instrument (GE Healthcare, Munich)
was employed to study the interaction between L19 IgG
or modified versions thereof and ED-B, Fcg RI/CD64
and Fcg RIIIA/CD16a. L19 IgG or modified versions
thereof were immobilized on a Biacore Sensor Chip
(Series S Sensor Chip CM5 treated with antibody cap-
ture kit, GE Healthcare). Soluble ED-B domain in sev-
eral concentrations (1.56 - 200 nM) or soluble Fc
receptor fragments Fcg RI/CD64 and Fcg RIIIA/CD16a
(R&D Systems) in several concentrations (1.56 - 50 nM)
were used as analytes. Association and dissociation
kinetics were detected to calculate the dissociation
constant.
Additional material
Additional file 1: Table S1. Test of Fc functionality after EPL and PTS.
The interaction with two Fcg receptors was analyzed by SPR.
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